Physician profile
Michael Joseph Devine
NPI 1245219419
$6,445.52
in general payments reported to CMS, 2019-2025
38 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $724 · 2021: $1,039 · 2022: $1,400 · 2023: $1,403 · 2024: $838 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.63 |
| Education | $140.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,104.70 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $870.77 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $676.23 | 2019-2023 | |
| Lilly USA, LLC | $483.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $448.94 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $360.72 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $317.76 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.35 | 2020-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $249.67 | 2022-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $193.22 | 2023-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $189.37 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.04 | 2019-2023 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $125.91 | 2019-2023 | Verquvo |
| Glaxosmithkline, LLC. | $111.21 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $106.82 | 2022-2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.